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To assess the current status of atrial ﬁbrillation (AF) ablation in Japan, the Japanese Heart Rhythm Society
(JHRS) instituted a national registry, the Japanese Catheter Ablation Registry of AF (J-CARAF).
Methods: Using an online questionnaire, the JHRS invited electrophysiology centers in Japan to voluntarily
and retrospectively register data regarding the AF ablation procedures performed in September, 2011.
Results: A total of 128 centers submitted data regarding AF ablation procedures in 932 patients (age
62.1710.4 years; male 76.8%; paroxysmal AF 65.7%, CHADS2 score 1.071.0). The majority received oral
anticoagulant therapy during and following the procedure (68.9% and 97.5%, respectively). Pulmonary vein
isolation (PVI) was performed in 97.5% of the patients; ipsilateral encircling PVI was the preferred technique
(79.7%). Three-dimensional (3D) mapping systems and irrigated-tip catheters were used in 94.8% and 87.7%
of the procedures, respectively. Ablation methods other than PVI were performed in 78.8% of all the patients
and 73.5% of the patients with paroxysmal AF. Acute complications were reported in 6.2% of the patients, but
no early deaths were recorded.
Conclusions: Ipsilateral encircling PVI, using 3D mapping and irrigated-tip catheters, is the standard AF
ablation method in Japan. However, adjunctive ablations were performed frequently, even in patients with
paroxysmal AF.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Catheter ablation procedures for arrhythmias such as supra-
ventricular tachycardia and atrial ﬂutter have become established
with excellent results. The permanent cure of tachycardias using
catheter ablation is possible. Pulmonary vein isolation (PVI) is a
cornerstone of atrial ﬁbrillation (AF) ablation [1–4]. Since itst Rhythm Society. Published by Els
shi Watanabe Hospital, 2-4-32
1 8651; fax: +81 6 6341 0785.introduction, signiﬁcant progress has been made in AF catheter
ablation; left atrial (LA) linear ablation [5–8], complex fractionated
atrial electrogram (CFAE) ablation [9] or defragmentation [10], non-
pulmonary vein (non-PV) foci ablation [11], and cardiac ganglion
plexus ablation [12,13] are effective adjunctive procedures of PVI for
treating non-PV AF triggers and substrates. However, systematic
indications for these adjunctive procedures have not yet been
established, and their selection is at the discretion of the attending
physician and institute. Reportedly, single-procedure AF ablation
has an efﬁcacy of 50–64% [14]. Therefore, AF ablation procedures
still have some obstacles to overcome.
It has also been reported that the incidence of complications
associated with AF ablation, such as pulmonary vein stenosis,evier B.V. All rights reserved.
Table 1
Background information of the patients who underwent atrial ﬁbrillation
ablation.
Number of cases n¼932
Age (y) 62.1710.4
Male, n (%) 716 (76.8)
Type of AF
Paroxysmal AF, n (%) 612 (65.7)
Persistent AF, n (%) 180 (19.3)
Long-standing persistent AF, n (%) 140 (15.0)
Frequency of paroxysmal AF attacks
o1/month 70 (11.4%)
o1/week 206 (33.7%)
o1/day 206 (33.7%)
K. Inoue et al. / Journal of Arrhythmia 29 (2013) 221–227222atrioesophageal ﬁstula, gastric hypomotility, and phrenic nerve
paralysis, differs from that associated with other catheter ablation
procedures [15], and their incidence in Japan remains to be
elucidated.
AF is the most common tachyarrhythmia in the Japanese
population, and AF ablation is increasingly used, despite the poorly
established indications for adjunctive ablation, a relatively high
recurrence rate, and speciﬁc complications. Determining the
current status of AF ablation in Japan is crucial. Therefore, the
Japanese Heart Rhythm Society (JHRS) instituted a nationwide
registry of AF-related catheter ablation: the Japanese Catheter
Ablation Registry of Atrial Fibrillation (J-CARAF). This registry
aimed to collect objective data to assess the performance and
safety of catheter ablation of AF in Japan.41/day 75 (12.3%)
Unknown 55 (9.0%)
Lone AF, n (%) 208 (22.3)
Congestive heart failure, n (%) 127 (13.6)
Age 65–74 years, n (%) 321 (34.4)
Age 475 years, n (%) 77 (8.3)
Hypertension, n (%) 483 (51.8)
Diabetes, n (%) 110 (11.8)
Stroke or TIA, n (%) 78 (8.4)
Vascular disease, n (%) 52 (5.6)
Coronary artery disease, n (%) 57 (6.1)
Dilated cardiomyopathy, n (%) 16 (1.7)
Hypertrophic cardiomyopathy, n (%) 37 (4.0)
Other cardiomyopathies, n (%) 7 (0.8)
Sick sinus syndrome, n (%) 67 (7.2)
Hyperthyroidism, n (%) 23 (2.5)
COPD, n (%) 20 (2.1)
Congestive heart disease, n (%) 8 (0.9)
Valvulardisease, n (%) 19 (2.0)
Chronic kidney disease on HD, n (%) 15 (1.6)
Post-open heart surgery, n (%) 22 (2.3)
Echocardiographic data
LVEF (%) 63.579.5
LA dimension (mm) 40.7715.2
LA volume (mL) 70.4733.8
History of anti-arrhythmic drug use (n) 1.270.9
Disopyramide, n (%) 81 (8.7)
Cibenzoline, n (%) 172 (18.5)
Aprindine, n (%) 47 (5.0)
Pilsicainide, n (%) 254 (27.3)
Flecainide, n (%) 141 (15.1)
Propafenone, n (%) 34 (3.6)
Bepridil, n (%) 218 (23.4)
Sotalol, n (%) 9 (1)
Amiodarone, n (%) 66 (7.1)
Others, n (%) 86 (9.2)
Average CHA2DS2-Vasc score 1.571.3
Distribution of the CHA2D2-Vasc score
0, n (%) 240 (25.8)
1, n (%) 276 (29.6)2. Materials and methods
The survey was performed retrospectively using an online
questionnaire. JHRS members were notiﬁed by mail. To facilitate
the calculation of the proportion of electrophysiological centers
capable of AF ablation, the ﬁrst questionnaire determined whether
catheter ablation for AF was performed in September, 2011. If AF
ablation procedures were performed within that period, precise
data on the patient background, AF ablation procedures, and the
strategies, results, and complications were collected. The patient
data included the age, gender, AF ablation procedure history,
AF type (paroxysmal, persistent, or long-standing persistent),
frequency of AF attacks in paroxysmal AF, thromboembolism risk
factors, structural heart disease, left ventricular ejection fraction,
left atrial (LA) volume and dimension estimated by echocardio-
graphy, and history of antiarrhythmic drug use. The AF ablation
procedure data included the procedural time, use of a three-
dimensional (3D) mapping system or irrigation catheter, use of
anticoagulant agents, anesthesia, and sedation, intraoperative
monitoring methods, and results of a post-procedure burst pacing
AF induction test. The AF ablation strategy data included the PVI
method, use of linear ablation of the LA roof or other sites, CFAE
ablation, ganglion plexus ablation, non-PV trigger foci ablation, or
cavotricuspid isthmus (CTI) ablation.
Continuous variables with a normal distribution were
expressed as mean7SD, and the data were compared between
the patient groups using an unpaired t-test. Variables that were
not normally distributed were expressed as the median (lower
quartile, upper quartile). The comparison of categorical variables
was accomplished using Fisher's exact test. Analyses were
conducted using the Stat View 5.0 software (SAS Institute;
NC, USA).2, n (%) 223 (23.9)
3, n (%) 119 (12.8)
4, n (%) 54 (5.8)
o5, n (%) 20 (2.1)
Average CHADS2 score 1.071.0
Distribution of the CHADS2 score
0, n (%) 326 (35.0)
1, n (%) 364 (39.1)
2, n (%) 162 (17.4)
3, n (%) 60 (6.4)
4, n (%) 15 (1.6)
o5, n (%) 5 (0.5)
Session of AF ablation
First session, n (%) 722 (77.5)
Second session, n (%) 184 (19.7)
Third session, n (%) 22 (2.4)
4 fourth session, n (%) 4 (0.4)
Abbreviations: AF; atrial ﬁbrillation, TIA; transient ischemic attack, COPD; chronic
obstructive pulmonary disease, HD; hemodialysis, LVEF; left ventricular ejection
fraction, LA; left atrium.3. Results
A total of 199 institutes voluntarily submitted data and 165
(83%) of those had an electrophysiological center capable of
catheter ablation in September, 2011; the majority (n¼128, 64%)
performed AF ablation during that period. A total of 932 sessions
were performed, with a median of 5 AF procedures (lower and
upper quartiles 2 and 9) per center per month. The largest center
performed 56 AF ablation procedures in the month.
Table 1 shows the patients' background data. The average age
was 62.1710.4 years, and 76.8% were male. Of all sessions, 77.5%
were ﬁrst AF ablation sessions, 19.7% were second sessions, and
2.8% were subsequent sessions. Patients with paroxysmal AF
constituted 65.7% of the patients; 89.6% of those suffered from
AF attacks more than once per week. The average CHADS2 and
CHA2DS2-VASc scores were 1.071.0 and 1.571.3, respectively.
Table 2
Atrial ﬁbrillation ablation procedures.
Number of cases n¼932
Pre-operative inspection
Transesophageal echocardiography, n (%) 745 (79.9)
Magnetic resonance imaging, n (%) 10 (1.1)
Computed tomography, n (%) 753 (80.8)
Procedure time (h) 3.671.3
Fluoroscopic time (min) 72.9752.7
Diagnostic and therapeutic instruments used
CARTO system, n (%) 676 (72.5)
EnSite system, n (%) 208 (22.3)
Irrigation catheter, n (%) 817 (87.7)
OAC use during the procedure, n (%) 643 (68.9)
Vitamin-K antagonist, n (%) 553 (59.3)
Direct thrombin inhibitor, n (%) 87 (9.3)
Factor Xa inhibitor, n (%) 3 (0.3)
Anesthesia
Local anesthesia, n (%) 30 (3.2)
Local anesthesia and light sedation, n (%) 405 (43.5)
Local anesthesia and deep sedation, n (%) 494 (53.0)
General anesthesia, n (%) 3 (0.3)
Intraoperative monitoring
Arterial pressure monitoring, n (%) 741 (79.5)
Oxygen saturation monitoring (SpO2), n (%) 932 (100)
End-tidal CO2 monitoring (ETCO2), n (%) 19 (2.0)
Bispectral Index (BIS), n (%) 106 (11.4)
Postoperative administration of steroid, n (%) 66 (7.1)
For treatment of pericarditis, n (%) 26 (2.8)
For recurrence prevention, n (%) 40 (4.3)
Table 3
Ablation strategies and acute results.
Number of cases n¼932
PVI, n (%) 910 (97.6)
Ipsilateral encircling PVI, n (%) 743 (79.7)
Box isolation, n (%) 54 (5.8)
Individual PVI, n (%) 96 (10.3)
Other PVI, n (%) 17 (1.8)
Adjunctive ablation, n (%) 731 (78.8)
In paroxysmal AF cases (n¼612), n (%) 450 (73.5)
In persistent AF cases (n¼180), n (%) 148 (82.2)
In long-standing persistent AF cases (n¼140), n (%) 131 (93.6)
Cavotricuspid isthmus ablation (CTI), n (%) 527 (56.5)
Adjunctive ablation other than CTI, n (%) 453 (48.6)
In paroxysmal AF cases (n¼612), n (%) 235 (38.3)
In persistent AF cases (n¼180), n (%) 103 (57.2)
In long-standing persistent AF cases (n¼140), n (%) 115 (82.1)
Ablation of CFAEs, n (%) 123 (13.1)
CFAEs in the LA, n (%) 119 (12.8)
CFAEs in the RA, n (%) 45 (4.8)
Focal ablation, n (%) 70 (7.5)
Focal ablation in the LA, n (%) 30 (3.2)
Focal ablation in the RA, n (%) 44 (4.7)
LA linear ablation, n (%) 238 (25.5)
LA rooﬂine ablation, n (%) 209 (22.4)
LA linear ablation other than a rooﬂine, n (%) 164 (17.6)
Superior vena cava (SVC) ablation, n (%) 155 (16.6)
Coronary sinus (CS) ablation, n (%) 44 (4.7)
Ganglion plexus (GP) ablation, n (%) 25 (2.7)
Electrical cardioversionduring the procedure 419 (40.3)
1 time, n (%) 228 (26.4)
2 times, n (%) 78 (9)
3 times, n (%) 16 (1.8)
44 times, n (%) 27 (3.1)
AF induction testing with burst pacing after ablation, n (%) 484 (55.4)
Induced and persisted for ≥5 min, n (%) 72 (8.2)
Induced and persisted for o5 min, n (%) 408 (43.8)
Cardiac rhythm at the end of the procedure
Sinus rhythm, n (%) 920 (98.7)
AF, n (%) 6 (0.6)
Other, n (%) 5 (0.5)
Adjunctive ablation was deﬁned as an ablation procedure other than PVI.
Abbreviations: PVI; pulmonary vein isolation, CFAE; complex fractionated electro-
gram, LA; left atrium, RA; right atrium, and AF; atrial ﬁbrillation.
Table 4
Comparison of ablation procedures in relation to atrial ﬁbrillation type.
PaAF n¼612 PeAF n¼180 LSPeAF n¼140 p-value
CTI ablation, n (%) 330 (53.9) 99 (55) 98 (70) 0.0022
SVC ablation, n (%) 105 (17.1) 24 (13.3) 26 (18.6) 0.38
Focal ablation, n (%) 40 (6.5) 16 (8.9) 14 (10) 0.28
CFAE ablation, n (%) 32 (5.2) 40 (22.2) 45 (32.1) o0.0001
Linear ablation, n (%) 92 (15) 57 (31.7) 89 (63.6) o0.0001
Abbreviations: PaAF; paroxysmal atrial ﬁbrillation, PeAF; persistent atrial ﬁbrilla-
tion, LSPeAF; long-standing persistent atrial ﬁbrillation, CTI; cavotricuspid isthmus,
SVC; superior vena cava, CFAE; complex fractionated atrial electrogram.
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a history of hypertension. The average left ventricular ejection
fraction and LA volume (dimension) were 63.579.5% and
70.4733.8 mL (40.7715.2 mm), respectively. The average num-
ber of antiarrhythmic drugs used was 1.270.9, and the 3 most
common drugs were pilsicainide (27.3%), bepridil (23.4%), and
cibenzoline (18.5%). However, 189 patients (20.2%) had no history
of antiarrhythmic drug use.
Table 2 shows the AF ablation procedure data. The preoperative
inspection consisted of transesophageal echocardiography and
cardiac computed tomography (CT) in 79.9% and 80.8%, respec-
tively; cardiac magnetic resonance imaging (MRI) was performed
in only 1.1% of the patients. Two 3D mapping systems were used
during PVI [16] in 94.8% of the patients: the CARTO system
(Biosense-Webster Inc., CA, USA) in 72.5% and EnSite system
(St. Jude Medical, MN, USA) in 22.3% of the patients. Irrigated
catheters were used in 87.7% of the patients. The procedure time
was 3.671.3 h, and ﬂuoroscopy time 72.9752.7 min.
Many centers performed AF ablation while the patients were
under anticoagulation therapy, which consisted of vitamin K
antagonists in 59.3%, direct thrombin inhibitors in 9.3%, and factor
Xa inhibitors in 0.3% of the patients.
Table 3 shows the AF ablation strategies. Because PVI is
considered the cornerstone of AF ablation, 97.6% of the patients
underwent PVI. Ipsilateral encircling PVI [17,18] (79.7%) was the
standard method; however, individual PVI (10.3%) [19] and box
isolation (5.8%) [20] were also performed at some centers. Ablation
adjunctive to PVI was performed in 78.5% of the patients. The CTI
and superior vena cava were ablated in 56.5% and 16.6% of the
patients, respectively. Adjunctive ablation other than CTI ablation
was performed in 453 patients (48.6%). The execution rate
depended on the AF persistence: 38.3% in paroxysmal AF, 57.2%
in persistent AF, and 82.1% in long-standing persistent AF
(po0.0001). LA linear ablation was performed in 25.5% of the
patients; of those, the ablation was on the LA roof in 22.4% and atother sites in 17.6%. The rate of CFAE ablation was 13.1%, and
consisted of LA CFAE ablation in 12.8% and right atrial CFAE
ablation in 4.8% of the patients. LA linear ablation was performed
more frequently than CFAE ablation (po0.0001). Seventy-four
patients (7.9%) underwent both LA linear ablation and CFAE
ablation. Finally, 98.7% of the AF ablation sessions resulted in
sinus rhythm.
Table 5
Complications of atrial ﬁbrillation ablation.
Number of cases n¼932
Total, n (%) 58 (6.2)
Pericardial effusion requiring drainage, n (%) 10 (1.1)
Pericardial effusion not requiring drainage, n (%) 19 (2.0)
Valve injury, n (%) 0 (0)
Transient high degree atrioventricular block, n (%) 1 (0.1)
Sinus arrest, n (%) 2 (0.2)
Transient ischemic attack, n (%) 0 (0)
Symptomatic cerebral infarction, n (%) 2 (0.2)
Asymptomatic cerebral infarction, n (%) 2 (0.2)
Pneumothorax, n (%) 0 (0)
Hemothorax, n (%) 1 (0.1)
Prolonged phrenic nerve paralysis, n (%) 1 (0.1)
Air embolism, n (%) 1 (0.1)
Severe pulmonary vein stenosis, n (%) 0 (0)
Hematoma at the puncture site, n (%) 11 (1.2)
Pseudoaneurysm, n (%) 4 (0.4)
Gastric hypomotility, n (%) 4 (0.4)
Death, n (%) 0 (0)
Table 6
Discharge prescription.
Number of cases n¼932
OAC use, n (%) 908 (97.5)
Vitamin-K antagonist, n (%) 761 (81.7)
Direct Thrombin inhibitor, n (%) 147 (15.8)
Factor Xa inhibitor, n (%) 0 (0)
Anti-platelet agents, n (%) 43 (4.6)
Antiarrhythmic drugs, n (%) 492 (53.6)
Disopyramide, n (%) 14 (1.5)
Cibenzoline, n (%) 57 (6.1)
Aprindine, n (%) 26 (2.8)
Pilsicainide, n (%) 79 (8.5)
Flecainide, n (%) 99 (10.6)
Propafenone, n (%) 23 (2.5)
Bepridil, n (%) 172 (18.5)
Amiodarone, n (%) 50 (5.4)
Others, n (%) 18(1.9)
Verapamil, n (%) 64 (6.9)
Beta-blocker, n (%) 253 (25.7)
Digitalis, n (%) 13 (1.4)
Angiotensin converting enzyme inhibitor, n (%) 51 (5.5)
AngiotensinII receptor blocker, n (%) 233 (25.0)
Statin, n (%) 153 (16.4)
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based on the types of AF. CTI ablation was performed in 53.9%, 55%,
and 70% of paroxysmal, persistent, and long-standing persistent AF
patients, respectively (p¼0.0022). There were no differences in
the frequencies of SVC ablation and focal ablation between the AF
types (p¼0.38 and p¼0.28, respectively). On the other hand, the
rates of CFAE ablation and linear ablation were highest in the
longstanding-persistent AF patients (32.1% and 63.6%) and lowest
in paroxysmal AF (5.2% and 15%).
Table 5 lists the complications of AF ablation. Pericardial
effusions occurred in 29 sessions (3.1%), and emergency drainage
of a cardiac tamponade was required in 10 sessions (1.1%).
Symptomatic cerebral infarctions occurred in two patients (0.2%),
and asymptomatic cerebral infarctions were diagnosed using CT or
MRI in two patients (0.2%). Other major complications were a
hemothorax in one patient; prolonged phrenic nerve palsy in one
patient; gastric hypomotility in four patients; and an air embolism
in one patient. No deaths were reported.
Table 6 shows the prescriptions at discharge. Most patients
(908, 97.5%) received oral anticoagulant (OAC) agents at discharge,such as warfarin in 761 patients (81.7%) and dabigatran in 147
patients (15.8%). Antiarrhythmic drugs were prescribed in 436
patients (53.6%); the three most frequently prescribed drugs were
bepridil (18.5%), ﬂecainide (10.6%), and pilsicainide (8.5%).4. Discussion
The J-CARAF was created in order to assess the status of AF
ablation in Japan today, as a supplement to the JHRS summary of
the Japanese Catheter Ablation Registry (JCAR) [21,22]. This is the
ﬁrst report of the J-CARAF, which describes the current indications,
procedures, strategies, and complications of AF ablation in Japan.
4.1. Electrophysiological centers performing atrial ﬁbrillation
ablation
Several years ago, the number of electrophysiological centers
performing AF ablation was small; AF ablation was considered
complicated and difﬁcult to accomplish, while its efﬁcacy and
indications were controversial. It is impressive that 78% of electro-
physiological centers performing catheter ablation in September
2011 also performed AF ablation in the same period. These data
indicate that the use of this procedure is rapidly increasing in
Japan, possibly because of technical developments, such as 3D
mapping systems, and an increase in the number of skilled
physicians. The guidelines of the Japanese Circulation Society
and American Heart Association, Advances and Controversies in
Atrial Fibrillation, and the Heart Rhythm Society (HRS) designate
facilities as Class I ablation facilities for drug refractory, sympto-
matic AF at electrophysiological centers performing more than
50 procedures per year [23,24]. In 68 centers, more than ﬁve AF
sessions were performed per month. Therefore, more than 50% of
the centers participating in this registry and performing AF
ablation might fulﬁll the criteria for a Class I designation.
4.2. Patients receiving atrial ﬁbrillation ablation
The average age of the patients undergoing AF ablation was
62.1710.4 years, which is relatively young for patients with AF.
Table 1 shows that lone AF was relatively uncommon, but
indicates that typical patients undergoing AF ablation were
middle-aged men with preserved LV function, mild LA remodeling,
a relatively low risk of cardiogenic cerebral infarctions, and
paroxysmal AF attacks occurring more than once a week. We can
speculate that the purpose of AF ablation was to improve a
compromised quality of life. The number of second AF ablation
sessions was 25% of the total ﬁrst sessions (184/722), indicating
the current re-ablation rate in Japan. Twenty-two patients under-
went a third AF ablation session, so the ratio of third sessions to
ﬁrst sessions was only 3%. Even though the efﬁcacy of AF ablation
over multiple procedures is estimated to be 73–81% [14], the
majority of patients who underwent AF ablation twice but experi-
enced recurrence declined a third session.
4.3. Ablation strategy
PVI was performed in 97.6% of the patients, constituting the
minimum necessary intervention for AF ablation in Japan (Table 3).
Of all the patients, 78.5% underwent adjunctive ablation other
than PVI, which was also performed in 73.5% of the patients with
paroxysmal AF. Interventions other than PVI and CTI ablation, such
as linear, focal, or CFAE ablation, were performed in 48.6% patients.
Although extensive ablation of non-PV AF substrates with linear or
CFAE ablation was recommended in patients with long-standing
persistent AF [4], those patients constituted only 15% of the total.
K. Inoue et al. / Journal of Arrhythmia 29 (2013) 221–227 225In fact, 38.3% of the patients with paroxysmal AF underwent
ablation other than PVI and CTI ablation. These data could indicate
that these extensive ablations are performed more often than
necessary. The rate of linear ablation (roof/mitral valve isthmus)
was signiﬁcantly higher than that of CFAE ablation (25.5% versus
13.1%, po0.0001). Japanese physicians preferred linear to CFAE
ablation for substrate modiﬁcation. However, physicians must
realize that creation of complete heart block, although difﬁcult
to accomplish, is recommended by the HRS, European Heart
Rhythm Association, and European Cardiac Arrhythmia Society
Expert Consensus Statement [4].
4.4. Ablation strategy based on AF types
CTI ablation and SVC ablation constituted a majority of the
ablation procedures adjunctive to PVI in patients with paroxysmal
AF. Although we did not collect data regarding the incidence of CTI-
dependent atrial ﬂutter and SVC ﬁring in this registry, the procedure
rates of CTI ablation (54%) and SVC ablation (17%) in paroxysmal AF
patients were estimated to be higher than their incidence [4].
Moreover, the frequencies of CTI and SVC ablation for paroxysmal
and persistent AF were almost the same. Therefore, we speculated
that CTI and SVC ablation procedures were routinely performed in
some centers regardless of their comorbid arrhythmias. Although
routine ablation of CTI and SVC would possibly prevent future
CTI-dependent atrial ﬂutter and SVC ﬁring, there is a risk of a
reconnection of the block line that could create an arrhythmic
substrate [25,26], leading to complications such as phrenic nerve
palsy. The question of whether or when routine CTI or SVC ablation
procedures might be appropriate is still controversial. The JHRS
plans to collect data on AF ablation follow-up that will enable an
evaluation of the efﬁcacy of CTI and SVC ablation procedures in
patients undergoing ablation for paroxysmal AF. Predictably, the
frequencies of substrate modiﬁcations, such as CFAE ablation and
linear ablation, increased with the duration of AF persistence. On the
other hand, the frequencies of ablation targeting AF triggers, such as
SVC ablation and focal ablation, were almost the same between the
AF types, which would indicate that these triggers play important
roles, even in patients with long-standing, persistent AF [27,28].
4.5. Periprocedural anticoagulation therapy
Data from this registry revealed 3 interesting points regarding
OAC use during AF ablation. First, the majority of electrophysiolo-
gical centers performed AF ablation while 68.9% of the patients
were still receiving OAC agents, which is a greater proportion than
previously reported [29]. OAC withdrawal prior to AF ablation has
been the subject of debate because undertaking procedures with
OAC agents could increase hemorrhagic complications. Recently,
some authors reported that periprocedural OAC therapy prevented
thromboembolic events without increasing fatal hemorrhagic
events [30–34]. These reports must have impacted the continuous
therapeutic anticoagulation during procedures. Second, the num-
ber of patients receiving OAC agents during the procedures
seemed large (68.9%), considering their low risk of cerebral
infarction. Although OAC indications are expanding, even the
latest guidelines do not recommend OAC use in patients with
CHADS2 or CHA2DS2-VASc scores of 0 [35], accounting for 35%
and 25.8% of the patients in this registry, respectively. It is possible
to speculate that physicians administer OAC agents to patients
without indications prior to ablation procedures, to prevent
periprocedural cerebral infarctions. Third, most patients (97.5%)
received OAC agents at discharge. Systemic anticoagulation is
recommended for all patients for at least 2 months following an
AF ablation procedure [4], because the atria are often stunned aftersinus conversion by ablation [36]. Physicians in Japan followed this
recommendation appropriately.
4.6. Complications of atrial ﬁbrillation ablation
AF ablation is a complex procedure and is consequently
associated with a relatively high risk of complications. Major
complications in the acute phase were evident in only 2.2%
of the patients (21/932), and no early deaths were recorded.
A previous worldwide survey of AF ablation complications
reported a major complication rate of 6%; 0.05% (4/8745) of
patients died following AF ablation [15]. Although the Japanese
complication rate tends to be lower than that in worldwide
surveys, the J-CARAF is a retrospective and voluntary survey and
may underestimate the complication rate because physicians who
encountered severe complications may hesitate to register their
results. Therefore, this complication rate should be interpreted as
the lowest estimate.5. Conclusions
Ipsilateral encircling PVI, using 3D mapping and an irrigated-
tip catheter, is the standard method of AF ablation in Japan.
Ablation methods other than PVI were also performed frequently,
even in patients with paroxysmal AF. Although the average
CHADS2 score was low, periprocedural OAC therapy was often
administered to prevent ablation-related thromboembolisms.
Attending physicians must know the standard indications, meth-
ods, and risks of AF ablation in the real world, make their own
interpretations and modiﬁcations, and use them based on the
experiences and activity of individual electrophysiological centers.Conﬂict of interest
None of the authors has any conﬂict of interest to declare.Appendix
This survey was conducted with the voluntary support of the
JHRS members. The following centers participated in the survey:
Akita Medical Center;
Anjo Kosei Hospital;
Asahikawa Medical University Hospital;
Edogawa Hospital;
Ehime University Hospital;
EP Expert Doctors-Team Tsuchiya;
Fujita Health University Hospital;
Fukuoka Sanno Hospital;
Gakkentoshi Hospital;
Gifu Prefectural General Medical Center;
Gunma Cardiovascular Center;
Gunma University Hospital;
Hamamatsu Medical Center;
Hayama Heart Center;
Hiratsuka Kyosai Hospital;
Hirosaki University School of Medicine and Hospital;
Hiroshima City Hospital;
Hiroshima Prefectural Hospital;
Hokkaido Medical Center;
Hokkaido University Hospital;
Hokko Memorial Hospital;
Hyogo Brain and Heart Center;
Hyogo College of Medicine Hospital;
K. Inoue et al. / Journal of Arrhythmia 29 (2013) 221–227226Ichinomiyanishi Hospital;
IMS Katsushika Heart Center;
Ishikawa Prefectural Central Hospital;
Izuo Hospital;
Japanese Red Cross Kumamoto Hospital;
Japanese Red Cross Kyoto Daini Hospital;
Jikei University Hospital;
Kagawa Prefectural Shirotori Hospital;
Kagoshima Medical Center;
Kameda Medical Center;
Kanazawa Medical University Hospital;
Kanazawa University Hospital;
Kansai Rosai Hospital;
Keio University Hospital;
Kimitsu Chuo Hospital;
Kitano Hospital;
Kitasato University Hospital;
Kobe City Medical Center General Hospital;
Kobe University Hospital;
Kokura Memorial Hospital;
Komaki City Hospital;
Konan Kosei Hospital;
Kumamoto Hospital;
Kurashiki Central Hospital;
Kushiro Kojinkai Memorial Hospital;
Kyoto University Hospital;
Kyoto-Katsura Hospital;
Kyushu Medical Center;
Kyushu University Hospital;
Maizuru Kyosai Hospital;
Matsue Red Cross Hospital;
Mie Heart Center;
Mie University Hospital;
Nagano Chuo Hospital;
Nagoya City East Medical Center;
Nagoya Daini Red Cross Hospital;
Nagoya Ekisaikai Hospital;
Nagoya University Hospital;
Nara Hospital Kinki University Faculty of Medicine;
Nara Medical University Hospital;
National Cerebral and Cardiovascular Center;
Nihon University School of Medicine, Itabashi Hospital;
Niigata University Medical and Dental Hospital;
Nippon Medical School Hospital;
Ogaki Municipal Hospital;
Ohta Nishinouchi Hospital, Ohta General Hospital Foundation;
Oita Medical Hospital;
Oita University Hospital;
Ome Municipal General Hospital;
Osaka City General Hospital;
Osaka City University Hospital;
Osaka General Medical Center;
Osaka Medical College Hospital;
Osaka Police Hospital;
Osaka Red Cross Hospital;
Osaka Rosai Hospital;
Saitama Medical University International Medical Center;
Saitama Red Cross Hospital;
Sakurabashi Watanabe Hospital;
Sapporo Medical University Hospital;
Self-Defense Forces Central Hospital;
Sendai City Hospital;
Sendai Kousei Hospital;
Shiga Medical Center for Adults;
Shiga University of Medical Science Hospital;
Shinshu University Hospital;Shiroyama Hospital;
Shizuoka General Hospital;
Shizuoka Medical Center;
Shizuoka Saiseikai General Hospital;
Shonan Hospital;
Showa University Fujigaoka Hospital;
Showa University Hospital;
Social Insurance Chukyo Hospital;
St. Marianna University School of Medicine Hospital;
Surugadai Nihon University Hospital;
Takai Hospital;
Takase Clinic;
Takeda Hospital;
The Cardiovascular Institute;
The Sakakibara Heart Institute of Okayama;
Toho University Ohashi Medical Center;
Toho University Omori Medical Center;
Tohoku University Hospital;
Tokushima Red Cross Hospital;
Tokuyama Central Hospital;
Tokyo Medical and Dental University, University Hospital of
Medicine;
Tokyo Medical University Hospital;
Tokyo Metropolitan Hiroo Hospital;
Tokyo Women's Medical University Hospital;
Tominaga Hospital;
Tottori Prefectural Central Hospital;
Toyama Prefectural Central Hospital;
Toyama University Hospital;
Toyohashi Heart Center;
Toyota Kosei Hospital;
Tsuchiura Kyodo General Hospital;
University Hospital, Kyoto Prefectural University of Medicine;
Yamagata University Hospital;
Yamaguchi University Hospital;
Yamanashi Kosei Hospital;
Yamato Kashihara Hospital;
Yokohama General Hospital;
Yokohama Minami Kyousai Hospital;
Yokohama Rosai Hospital; and
Yokosuka Kyosai Hospital.References
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